Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes

An Individual Patient Data Meta-analysis of 9,153 Patients

by Shama D. Ahuja, David Ashkin, Monika Avendano et al.
PLoS Med 9(8): e1001300 (28 August 2012)

16 pp. 663 kB:;jsessionid=0A1FE076A28E65C7F811CC05CEFC4F6F?

Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. The authors undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB. In this analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment.

(Visited 20 times, 1 visits today)
This entry was posted in General, Tuberculosis. Bookmark the permalink.